CDC Website CDC Website

To Join the NPIN community or

You are here

Commercial Organizations

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21)

NPIN admin's picture

Grant Amount: Unspecified. This FOA offers the opportunity to conduct exploratory clinical and basic research focused on prevention and treatment of HCV for at-risk substance using populations, including those infected with or at risk for HIV. The R21 mechanism supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. An R21 grant application need not have extensive background material or preliminary information.

Reduce Hepatitis Infections by Treatment and Integrated Prevention Services (Hepatitis-TIPS) among Non-urban Young Persons W...

NPIN admin's picture
Grant Amount: Estimated total funding available including direct and indirect costs for first year $600,000; Estimated total funding available including direct and indirect costs for entire project period $1,800,000. The purpose and overarching goal of this cooperative agreement is to address the high prevalence of viral hepatitis C infection by developing and implementing an integrated approach for detection, prevention, care and treatment of Hepatitis C infection among young (18-30 year old), non-urban people who inject drugs (PWID).

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01)

NPIN admin's picture
Grant Amount: Unspecified. This Funding Opportunity Announcement (R01) outlines priority areas for high impact clinical and basic research for at-risk substance using populations, including those infected with or at risk for HIV. In particular, this FOA encourages research focused on prevention and treatment of Hepatitis C Virus (HCV) to reduce new infections and identify and treat existing infections more effectively.

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34)

NPIN admin's picture
Grant Amount: Direct costs are limited to $450,000 over a three-year period, with no more than $225,000 direct costs allowed in any single year. This FOA (R34) offers the opportunity to conduct the initial development of a clinical trial or research project focused on prevention and treatment of HCV for at-risk substance using populations, including those infected with or at risk for HIV.

Project SOAR (Supporting Operational AIDS Research)

NPIN admin's picture
Grant Amount: Anticipates a maximum total of $70 million over five years under this RFA. The United States Government, represented by the United States Agency for International Development (USAID) Bureau for Global Health (BGH), Office of HIV and AIDS is seeking applications from qualified applicants for funding of a Cooperative Agreement. The purpose of this RFA is to provide support for an organization to conduct operational HIV and AIDS research, promote utilization and dissemination of data, and build the capacity of local organizations to conduct operational research.

Accelerating Improvements in the HIV Care Continuum (R21)

NPIN admin's picture
Grant Amount: Unspecified. This Funding Opportunity Announcement (FOA) encourages innovative studies to address gaps in HIV care continuum research. The HIV care continuum has provided a useful framework for tracking progress towards the National HIV/AIDS Strategy (NHAS) HIV-testing and HIV-treatment goals, and helped to guide a growing body of research to better understand and intervene at one or more steps in the continuum.

Accelerating Improvements in the HIV Care Continuum (R01)

NPIN admin's picture
Grant Amount: Unspecified. This Funding Opportunity Announcement (FOA) encourages innovative studies to address gaps in HIV care continuum research. The HIV care continuum has provided a useful framework for tracking progress towards the National HIV/AIDS Strategy (NHAS) HIV-testing and HIV-treatment goals, and helped to guide a growing body of research to better understand and intervene at one or more steps in the continuum. Yet, there are some aspects of entering and remaining in HIV care that are relatively less studied than other areas, and merit urgent attention.

NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1)

NPIN admin's picture
Grant Amount: NIDA intends to commit $2M in each fiscal year (FY15-FY17) to fund 2-3 awards each year. This award is designed to support individual scientists of exceptional creativity who propose cutting edge – and possibly transformative – approaches to major challenges in biomedical and behavioral research on HIV/AIDS that are relevant to drug abuse. The term “avant-garde” is used to describe highly innovative approaches and ideas that have the potential to be transformative.

Pages

Subscribe to RSS - Commercial Organizations